{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.56","upperLimit":"7.13","value":"3.35"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"3.06","upperLimit":"NA","value":"6.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Progressive Disease (PD): At least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who had progressed on at least one prior line of treatment for their recurrent and/or metastatic HNSCC\n\nParticipants were treated with Nivolumab and Cetuximab at recommended Phase II dose (RP2D). Nivolumab: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms. Cetuximab: Cetuximab intravenously (IV) at 500 mg/m\\^2 or 250 mg/m\\^2 as outlined in the treatment arms.","id":"OG000","title":"Phase I Lead in + Phase II: Cohort A"},{"description":"Patients who have not had any prior treatment for their recurrent and/or metastatic HNSCC\n\nParticipants were treated with Nivolumab and Cetuximab at recommended Phase II dose (RP2D). Nivolumab: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms. Cetuximab: Cetuximab intravenously (IV) at 500 mg/m\\^2 or 250 mg/m\\^2 as outlined in the treatment arms.","id":"OG001","title":"Phase II - Cohort B"}],"paramType":"MEDIAN","populationDescription":"Evaluable participants","reportingStatus":"POSTED","timeFrame":"at 12 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}